Nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma previously treated with sorafenib: 5-year results from CheckMate 040.
Saved in:
| Title: | Nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma previously treated with sorafenib: 5-year results from CheckMate 040. |
|---|---|
| Authors: | Melero I; Department of Immunology, Clinica Universidad de Navarra and CIBERONC, Pamplona, Spain. Electronic address: imelero@unav.es., Yau T; Department of Medicine, University of Hong Kong, Hong Kong, China., Kang YK; Department of Oncology, Asan Medical Center, University of Ulsan, Seoul, South Korea., Kim TY; Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea., Santoro A; Humanitas University and IRCCS Humanitas Research Hospital - Humanitas Cancer Center, Rozzano, Italy., Sangro B; Liver Unit and HPB Oncology Area, Clinica Universidad de Navarra and CIBEREHD, Pamplona, Spain., Kudo M; Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka, Japan., Hou MM; Chang Gung Memorial Hospital, Chang Gung University, Taipei, Taiwan., Matilla A; Hospital General Universitario Gregorio Marañón CIBEREHD, Madrid, Spain., Tovoli F; Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy; Division of Internal Medicine, Hepatobiliary and Immunoallergic Diseases, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy., Knox J; Princess Margaret Cancer Centre, Toronto, Canada., He AR; Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA., El-Rayes B; Department of Hematology and Medical Oncology, University of Alabama at Birmingham, Birmingham, USA., Acosta-Rivera M; Fundacion de Investigacion, San Juan, Puerto Rico., Lim HY; School of Medicine, Sungkyunkwan University, Seoul, Korea., Soleymani S; Bristol Myers Squibb, Princeton, USA., Yao J; Informatics and Predictive Sciences, Bristol Myers Squibb, Princeton, USA., Neely J; Translational Medicine, Bristol Myers Squibb, Princeton, USA., Tschaika M; Oncology Clinical Development, Bristol Myers Squibb, Princeton, USA., Hsu C; National Taiwan University Hospital, Taipei, Taiwan; National Taiwan University Cancer Center, Taipei, Taiwan., El-Khoueiry AB; USC Norris Comprehensive Cancer Center, Los Angeles, USA. |
| Source: | Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2024 Jun; Vol. 35 (6), pp. 537-548. Date of Electronic Publication: 2024 May 22. |
| Publication Type: | Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial |
| Journal Info: | Publisher: Elsevier Country of Publication: England NLM ID: 9007735 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1569-8041 (Electronic) Linking ISSN: 09237534 NLM ISO Abbreviation: Ann Oncol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
